08.05.2014

AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients

more...

04.11.2013

AiCuris, 4SC Discovery and CRELUX announce drug discovery collaboration

more...

29.01.2013

AiCuris Surpasses 50% Enrollment Milestone in Phase II Superiority Trial for Herpes Drug Pritelivir

more...

27.11.2012

After license deal for letermovir: Head-to-head phase 2 trial initiated by AiCuris to demonstrate superiority of its novel drug pritelivir vs. valacyclovir for treatment of genital herpes

more...

15.10.2012

Aicuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus

more...

07.08.2012

AiCuris promising drugs against Herpes simplex (AIC316) and Human Cytomegalovirus (Letermovir, AIC246) in preparation for phase III:

more...

16.04.2012

Better prevention of transmission and lesion development of genital herpes predicted for AiCuris drug AIC316 Data showing stronger reduction of clinically relevant viral shedding in comparison with nucleosides to be presented at upcoming conferences

more...

02.04.2012

Results of Letermovir (AIC246) Phase 2b in Prophylaxis of Human Cytomegalovirus in Recipients of Human Blood Precursor Cell Transplants meeting both primary Efficacy Endpoints to be presented at International Conferences

more...

14.02.2012

AiCuris Drug Letermovir (AIC246) meets primary efficacy endpoints in phase 2 for human cytomegalovirus (HCMV) prophylaxis in human blood precursor cell recipients

more...

05.01.2012

AiCuris receives Orphan Drug Designation for Letermovir (AIC246) from FDA

more...

17.09.2011

New Data on Letermovir (AIC246) presented at 51st ICAAC

more...

05.09.2011

No resistant herpes simplex virus (HSV) observed in phase II trial with AIC316, AiCuris' novel herpes drug

more...

29.08.2011

HCMV DRUG Letermovir (AIC246) receives Fast Track from FDA. New data at 51st ICAAC

more...

18.07.2011

AiCuris’ novel HSV compound AIC316 shows efficacy in phase II

more...

21.04.2011

AiCuris receives Orphan Drug Designation for its innovative phase II drug AIC246 for the prevention of HCMV disease

more...

08.12.2010

AiCuris completes Phase II genital herpes trial with AIC316 ahead of time

more...

29.11.2010

AiCuris gained Bio.NRW research promotion

more...

05.11.2010

AiCuris Presents Preclinical and Phase 1 Data of its anti-HSV drug AIC316

more...

21.10.2010

AiCuris Announces AIC246 to be Successful in Treatment of Multiorgan HCMV Disease

more...

15.09.2010

The 50th ICAAC, Boston AiCuris presents Phase I Safety and PK Data of the novel anti-HCMV terminase inhibitor AIC246

more...

19.07.2010

AiCuris presents mechanism of action investigations of its novel anti-HCMV drug AIC246 at the International Herpesvirus Workshop

more...

01.07.2010

AiCuris’ novel resistance breaking HIV compound AIC292 in Phase I

more...

10.05.2010

Novel HCMV compound of AiCuris in phase IIb trial with bone marrow transplant recipients

more...

14.04.2010

AiCuris raises 55 Mio EUR (75 Mio USD)

more...

06.11.2009

AiCuris successfully completed phase I for novel herpes compound

more...

15.09.2009

AiCuris’ novel HCMV compound shows good tolerability and efficacy in phase II study

more...

26.08.2009

AiCuris to present phase II data for HCMV compound at ICAAC

more...

If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact us.